To identify more effective biomarkers to screen the real beneficiaries of EGFR-TKI-resistant NSCLC patients from ICI plus chemotherapy, we systematically analyzed the indicators in peripheral blood, which is now acknowledged as a vital important pool to explore biomarkers. This evidence concerns the gene EGFR and non-small cell lung carcinoma.